ImpediMed secures FDA clearance to expand SOZO into sarcopenia risk assessment
ImpediMed (ASX: IPD) has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its SOZO Digital Health Platform for sarcopenia risk assessment. Under the new indication, the SOZO system may be used to assess patients at risk of sarcopenia, a disease of low muscle mass or muscle loss.
The clearance makes SOZO the only FDA-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of sarcopenia risk. It adds a new clinical indication to a device many oncology teams already use, with the capability set to arrive alongside the upcoming SOZO software release (v6.3), expected in Q2 FY27.
When big ASX news breaks, our subscribers know first
Why this clearance matters
The indication opens SOZO to a large and often under-served monitoring gap. Sarcopenia is frequently missed in clinical practice, in part because the reference-standard tools were never built for fast, repeatable assessment.
Clinical prevalence data underlines the scale of the opportunity:
-
Sarcopenia develops in roughly one in three breast cancer patients during chemotherapy and is associated with worse outcomes.
-
It also affects patients with chronic conditions such as heart failure and metabolic disorders including type 2 diabetes and obesity.
-
It frequently goes undetected, as reference-standard tools, dual-energy X-ray absorptiometry (DXA) and computed tomography (CT), are not designed for the fast, repeatable monitoring that early detection requires.
For investors, the significance is straightforward. The clearance expands SOZO’s addressable use cases beyond lymphedema into a sizeable, under-served monitoring gap, and it does so using the same existing scan.
What is sarcopenia, and why it matters for investors
Sarcopenia is a progressive skeletal muscle disorder, defined as low muscle mass combined with reduced strength or function. In oncology, it can precede a diagnosis, result from the cancer itself, or be driven by treatment through inflammation, metabolic stress, reduced activity and poor nutrition.
The clinical stakes are considerable. Patients who lose muscle tend to tolerate chemotherapy less well, face more potential complications, and can recover more slowly. Low skeletal muscle mass is associated with worse survival in patients with breast cancer.
Critically, sarcopenia is modifiable. Resistance exercise and optimised nutrition can rebuild muscle, and because the condition grows harder to reverse over time, early detection matters. Muscle loss can also hide behind a stable weight or a normal body mass index (BMI), reinforcing the need for a tool that separates muscle from fat.
The investor takeaway is clear. A condition that is both modifiable and frequently missed builds a strong clinical case for routine screening, which in turn supports better disease management.
How SOZO assesses sarcopenia risk
SOZO uses bioimpedance spectroscopy (BIS), measuring impedance across 256 frequencies (from 3 kHz to 1000 kHz) to differentiate intracellular and extracellular fluid and to estimate lean and skeletal muscle mass. Where single-frequency bioelectrical impedance analysis (BIA) offers just one snapshot, the full spectrum resolves body composition with the precision a clinical decision requires.
A quick, non-invasive scan produces immediate results, making it practical for the serial monitoring that tracking muscle over time demands. This contrasts with the reference-standard imaging alternatives, which are accurate but not designed for frequent, repeated use.
| Assessment method | How it works | Limitation for routine monitoring |
|---|---|---|
| SOZO (BIS) | Quick, non-invasive scan with immediate results across 256 frequencies | Practical for serial monitoring |
| DXA | Reference-standard imaging | Requires a dedicated appointment |
| CT | Reference-standard imaging | Radiation exposure; typically reserved for staging |
Supporting evidence reinforces the case. In patients with early breast cancer, sarcopenia detected by BIS was associated with more than double the odds of chemotherapy toxicity, and researchers concluded that BIS is a high-value, radiation-free alternative to CT for sarcopenia assessment.
The workflow advantage is notable. The assessment is drawn from SOZO’s BodyComp™ muscle-mass indices, taken from the same scan oncology teams already use to monitor for lymphedema and track body composition.
Management commentary
Erik Anderson, CEO & Managing Director, ImpediMed
“Sarcopenia is one of the most consequential and most overlooked risks in cancer care. Patients lose muscle during treatment, and too often no one catches it until the damage is done. Expanding SOZO into sarcopenia risk assessment means clinicians now have a practical way to see what’s happening inside the body, from a simple scan that fits right into their workflow. Getting there sooner means patients have a better chance of staying strong enough to finish treatment, recover well, and reduce their risk of cancer recurrence. This clearance is a meaningful step forward for SOZO’s capabilities, and we look forward to making it available to clinicians.”
External validation was offered by Dr Jay K. Harness, MD, FACS, FASBrS, Founder of CancerFitness.org and a Past-President of the American Society of Breast Surgeons (ASBrS), who noted that flagging muscle-loss risk early from a routine scan means clinicians can act while the condition is still reversible.
What’s next for ImpediMed
The focus now turns to the commercialisation roadmap. Key next steps include:
- The sarcopenia capability is expected to launch with the SOZO software release v6.3 in Q2 FY27.
Executing on that roadmap depends on ImpediMed’s balance sheet position, which was materially strengthened by a $15.2 million capital raise structured across an institutional placement and a share purchase plan, alongside at least $5 million in annualised cost reductions targeting cash flow breakeven in FY28.
-
It leverages the existing installed base, with clinics already using SOZO.
-
It adds a new clinical indication, alongside lymphedema and heart failure fluid status, on a single device.
The sarcopenia clearance lands inside a broader three-market expansion strategy that ImpediMed has been executing across oncology, heart health, and weight management, targeting a combined addressable market of more than $1.5 billion using the same installed SOZO base.
Get Healthcare Breakthroughs Like This in Your Inbox First
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.